万邦德医药控股集团股份有限公司 关于石杉碱甲控释片II/III期临床试验 完成100例受试者入组的公告

Core Viewpoint - The company has completed the enrollment of 100 subjects for the Phase II/III clinical trial of Huperzine A Controlled-Release Tablets, a new drug for treating mild to moderate Alzheimer's disease, indicating progress in its drug development efforts [1][3]. Group 1: Product Information - Product Name: Huperzine A Controlled-Release Tablets - Drug Classification: Category 2.2 new drug - Indication: Mild to moderate Alzheimer's disease - Dosage Form: Tablet, 0.2mg [1][2] - The drug is a cholinesterase inhibitor aimed at improving cognitive function, showing potential in preclinical studies to slow the progression of Alzheimer's disease and offering various benefits, including reducing β-amyloid protein, anti-inflammatory, antioxidant stress, and neuroprotective effects [1]. Group 2: Clinical Trial Details - The company is collaborating with over 50 research institutions nationwide, including Capital Medical University Xuanwu Hospital, to further validate the drug's safety and efficacy [3]. - The controlled-release technology allows for a smoother drug release profile, enhancing patient convenience and adherence by supporting once-daily dosing [2].